press release

The closed-loop BCI system, developed entirely in Germany, is currently being evaluated in an FDA-approved clinical trial with stroke patients at Harborview Medical Center in Seattle, a part of UW Medicine   Freiburg, Germany, July 29, 2025 – CorTec GmbH, a pioneer in active implantable medical technologies, today announced the first human implantation of its […]

A Strengthened Leadership Team to Accelerate Growth and Innovation   CorTec GmbH, a pioneer in active implantable technologies and Brain-Computer Interface (BCI) systems, is pleased to announce the appointment of Dr. Frank Desiere as its new Chief Executive Officer (CEO). This significant leadership milestone highlights CorTec’s commitment to driving innovation and growth in the rapidly

CorTec GmbH, a leader in innovative implantable technologies, is pleased to announce a strategic partnership with Heraeus Medevio, based in Minneapolis, USA. This collaboration aims to support customers in the neuromodulation sector, from concept and small series production (CorTec) to large series production (Medevio). Together, the companies will deliver next-generation medical devices and drive innovation

CorTec has announced today that Institutional Review Board from University of Washington (IRB) has approved the Feasibility study for stroke rehabilitation using the Brain Interchange System. This marks a significant milestone and paves the way for the system’s clinical investigation in the United States. The IRB approval follows the recent Investigational Device Exemption (IDE) granted

CorTec has announced today that the US Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application by the University of Washington School of Medicine (UW) involving the closed-loop Brain Interchange Implant System. This clinical study will investigate a novel stroke rehabilitation treatment using cortical stimulation to enhance plasticity within the brain.

German medical technology innovator poised to make waves after implantation of a brain chip by Neuralink in a human trial As it prepares for the next stage of its groundbreaking device for the treatment of stroke, CorTec GmbH, a pioneering German medical technology company, is poised to make significant strides in the field of neurotechnology.

Dr. Oliver Bärtl joins CorTec’s executive leadership team. Prof. Dr. Tim Denison, Prof. Dr. Pascal Fries, Dr. Christoph Mangold and Helmut Jeggle become new members of CorTec’s Advisory Board. CorTec GmbH, a Medical Device innovation leader located in Freiburg, Germany, announced that Dr. Oliver Bärtl has been appointed Chief Executive Officer. He complements the existing

Dr. Harald Poth, Marco Winzer and Prof. Dr. Pascal Fries new members of CorTecs Advisory Board Following the conclusion of a new round of investments last fall, CorTec is now expanding the expertise in the two advisory boards of the medical technology company. Dr. Harald Poth from LBBW Venture Capital GmbH joins the company’s Advisory

Today CorTec announced the close of a €13 million funding. The investor consortium is led by Santo Venture Capital, the Strüngmann family holding company. Alongside LBBW Venture Capital, several existing shareholders participate in the funding round. Based on the investments, CorTec plans the next step of expansion with a subsidiary in the USA and the

CorTec and the Wyss Center, a non-profit neurotechnology translation organization, have signed a partnership agreement. They will collaborate in developing a novel, minimally invasive brain monitoring and stimulation device. The partners will work together on research, design and development of a device for continuous, long-term, monitoring of the brain’s electrophysiological signals for clinical diagnostic and